Previous studies of esophageal squamous cell carcinoma (ESCC) have shown a high frequency of allelic loss on chromosome 13q, infrequent somatic mutations in BRCA2, and a suggested association between a positive family history (FH þ ) of upper gastrointestinal cancer and germline BRCA2 mutations. In all, 70 ESCC patients (44 FH þ and 26 FHÀ) were examined by direct full sequencing of germline DNA for BRCA2 mutations. In addition, 28 family members of three of these patients and 232 unrelated healthy blood bank donor controls were examined for the mutations identified in the 70 ESCC patients. Five BRCA2 germline mutations, including three not previously reported (N1600del, A2054P, and V2109I), were identified in six of 44 FH þ patients, but none of 26 FHÀ patients (14 vs 0%, P ¼ 0.078), consistent with our previous findings (3/34 or 9% FH þ vs 0/22 or 0% FHÀ, P ¼ 0.27). The cumulative frequency of BRCA2 germline mutations in ESCC patients in this and our previous study combined is 12%, with all mutations found in FH þ as opposed to FHÀ cases (9/78 or 12% FH þ vs 0/48 or 0% FHÀ, P ¼ 0.013). We conclude that germline mutations in BRCA2 in ESCC patients from this high-risk area of China are more frequent in FH þ than FHÀ cases, suggesting that BRCA2 may play a role in genetic susceptibility to familial ESCC.
Introduction
Esophageal squamous cell cancer (ESCC) is one of the most common fatal tumors worldwide; however, its molecular etiology remains largely unknown. The disease occurs at a high rate in several distinct geographic regions, including Shanxi Province in northern China. Epidemiological studies have shown that tobacco and alcohol are the major risk factors for esophageal cancer (EC) in the low-risk populations of Europe and North America, but the etiology of this tumor in high-risk populations remains less clear. In addition to environmental factors (Li et al., 1980; Li, 1982) , there are at least four lines of evidence supporting a role for genetic susceptibility in the etiology of ESCC in the high-risk populations of north central China. These include the association of a positive family history with increased risk of developing this cancer (Hu et al., 1991; Wang et al., 1993) ; evidence of familial aggregation of the disease (Li and He, 1986; Wu et al., 1989; Hu et al., 1992) ; segregation analyses among high-risk family pedigrees, which suggest an autosomal recessive Mendelian pattern of inheritance (Carter et al., 1992) ; and cytogenetic studies, which have found that chromosomal instability, as measured by increased chromosomal aberration rates, fragile sites, and/or sister chromatid exchanges, is much more common in ESCC cases and their healthy relatives than in healthy persons from families without a history of ESCC (Wu et al., 1989) . In order to search for genes involved in the development and/or progression of ESCC in patients from Shanxi Province, previously we performed several studies of loss of heterozygosity (LOH) in ESCC patients. A genome-wide scan of allelic deletion showed a very high frequency of LOH on chromosome 13 (Hu et al., 2000) , which we confirmed with the subsequent fine mapping of LOH on this chromosome . These data also showed two common deletion regions (including one on 13q12.3-q13.1, where BRCA2 is located) and a significantly higher frequency of LOH in patients with a positive family history (FH þ ) of upper gastrointestinal (UGI) cancer compared to patients with no family history (FHÀ). To assess whether BRCA2 was the inactivation target for allelic loss on chromosome 13 in ESCC, we examined the entire coding sequence of BRCA2 for mutations, using single-strand conformation polymorphism (SSCP) analysis and DNA sequencing in the same group of 56 patients. Eight mutations were identified in five patients, including three germline and two somatic mutations (Hu et al., 2002) . Although the frequency of germline BRCA2 mutations (9%) was relatively low, all the three germline mutations detected were in patients with a family history of UGI cancer, suggesting a possible association between family history of UGI cancer and mutations in BRCA2.
In the present study, we selected 70 ESCC patients, including 44 FH þ (average age 53.7 years) and 26 FHÀ cases (average age 48.9 years), to perform BRCA2 germline mutation testing using full sequencing (Table 1) . As a part of our ongoing family study being conducted in Shanxi Province, we also had germline DNA available for evaluation from 28 first-degree relatives of three of the mutation-positive ESCC cases. Finally, we examined DNA from 232 unrelated healthy blood bank donors as controls, including 101 from Beijing and 131 from Yangcheng, Shanxi Province, to confirm that the BRCA2 germline mutations observed were not simply novel single-nucleotide polymorphisms (SNPs) in Chinese.
Results
Full sequencing of the BRCA2 gene revealed that six of 44 FH þ group ESCC patients (14%) had five germline mutations, while no mutations were found in the FHÀ group (P ¼ 0.078, Fisher's exact test). The five germline mutations included four missense mutations (Q2580H, A2054P, V2109I in one patient each, and C315S in two patients) and one deletion (N1600del) (Nos. 1-8, Table 2 ). The potential risk factors in these patients are also shown in Table 2 . No breast or ovarian cancers were reported in the families of these patients. Three of these mutations (Q2580H, A2054P, N1600del) have not been reported in the Breast Cancer Information Core (BIC) database, http://research.nhgri.nih.gov/bic. In total, 28 family members from the three FH þ patients (L002-01, L012-01, and L014-01), whose family collections were considered complete, were tested for the same mutation identified in the case from that same family. Pedigrees and genotypes for these three families are shown in Figures 1-3 .
In family L002 (N ¼ 11, including patient 01; Figure 1 ), the proband (01) was diagnosed with EC at age 39 years and determined to have a germline alteration (N1600del), which results in deletion of a single amino acid (Asn or N) in exon 11 of BRCA2. His father and maternal grandmother both died of EC at ages 69 and 82 years, respectively. The N1600del was identified in half of the relatives tested, including the BRCA2 germline mutations in esophageal cancer N Hu et al patient's mother, four of five siblings (03, 09, 10, 11), and one of two maternal uncles (07), but in neither of the two paternal uncles. We reconstructed the genotype for the patient's father (02) using results from his children and wife, and determined that 02 is unlikely to carry this mutation, suggesting that the N1600del was transmitted via the maternal side with segregation in the nuclear family of the proband.
In family L012 (N ¼ 8, including patient 01; Figure 2 ), a missense mutation (C315S) was identified in the proband (01), two of her siblings (03, 08), and one maternal niece (07). The proband's sister (02) also died of EC, but had no source of DNA for testing; so we reconstructed her genotype as being a mutation carrier, based on her husband (05, noncarrier), one daughter (06, noncarrier), and a second daughter (07, carrier). Taken together, these results indicate that both sisters with EC in this family carried the same mutation (C315S), although it is unclear which side of the family the mutation came from.
In family L014 (N ¼ 12, including patient 01; Figure 3 ), a missense mutation (Q2580H) was identified, including the proband (01), whose mother died of cervical cancer, and two of his siblings (05, 07). The proband's paternal cousin (02) also died of ESCC. However, 02's wife, four children, and five siblings all tested negative for this mutation; so we were unable to reconstruct 02's genotype for this alteration.
None of the five mutations found in the ESCC cases was identified in healthy individuals from either our lowor high-risk regions, with the exception of the C315S alteration that was seen in a single individual from the high-risk region. Overall, this suggests that the five germline mutations studied here are not novel SNPs in the Chinese population, as the frequencies were less than 1% for each.
Variant K2729N, identified in two of 70 ESCC patients studied here, has previously been reported as a missense mutation in the BIC database. We also found this variant in seven of 232 (3%) healthy controls (2/101 or 2% in the low-and 5/131 or 4% in the high-risk population), suggesting that K2729N is a novel polymorphism rather than a disease-specific mutation in Chinese. In addition to the alterations described above, 14 SNPs in BRCA2 were identified in the 70 ESCC patients (Table 3) . The frequencies of five of these SNPs were 450%, including three nonsynonymous and two synonymous variants. Narod, 2002) . Most of the deleterious alterations described in BRCA2 are frameshift mutations that result in a truncated protein; however, in many cases of hereditary breast and ovarian cancer, amino-acid changes of unknown significance are seen. Recent studies reveal that the BRCA2 protein is required for maintenance of chromosomal stability in mammalian cells and functions in the biological response to DNA damage, as evidenced by the finding that mutations in BRCA2 lead to chromosomal instability due to defects in the repair of double-strand and single-strand DNA breaks (Yang et al., 2002) . Earlier studies have shown a very high level of chromosomal instability in ESCC from this high-risk area of China, observations consistent with a defect in chromosomal instability (Wu et al., 1989; Hu et al., 2000; Li et al., 2001) . In this study, we identified a higher frequency of BRCA2 germline mutations in FH þ ESCC patients compared to FHÀ patients (14% vs none), consistent with our previous study (9% vs none (Hu et al., 2002) ). The data from these two studies combined indicate that the frequency of germline mutations is significantly higher in FH þ cases than in FHÀ cases (12% vs none; P ¼ 0.013; relative risk ¼ 1.7, 95% confidence interval 1.5-2.0). Although ESCC is one of the most common fatal tumors worldwide and previous studies have shown a high frequency of LOH on 13q12 in this tumor, only two groups have reported on BRCA2 mutations in ESCC to date, including Harada (Harada et al., 1999) and our group (Hu et al., 2002) . In light of the extensive previous evidence linking ESCC with a positive family history of UGI cancer (Li and He, 1986; Wu et al., 1989; Hu et al., 1991 Hu et al., , 1992 Carter et al., 1992; Wang et al., 1993) , it is particularly interesting that we have now observed a significant difference in the rate of germline mutations in BRCA2 between familial and sporadic ESCC patients. Taken together, these data support a role for germline mutations in BRCA2 in the genetic susceptibility of familial ESCC in this high-risk area of China, and suggest a possible link with the high rate of genetic instability observed on chromosome 13q. Two of the BRCA2 germline mutations identified here (C315S and N1600del) showed segregation of the mutation in the families studied, but we could not demonstrate cosegregation with disease. In one of these families (L012), both the two sibling cases carried the same C315S mutation, as did two other unaffected siblings. The C315S mutation was also observed in two other ESCC patients who were not part of the family linkage study, including one first evaluated as part of this study and another described in an earlier study (Hu et al., 2002) . Both of these cases had a positive family history of EC (nos. 7 and 10 in Table 2 ). In addition to these ESCC cases with the C315S mutation, we also identified this variant in one healthy control from the high-risk area, but this person's family history of cancer is unknown. Altogether, from this and our previous study, the C315S mutation was identified in three of 78 (4%) ESCC FH þ patients, but was not seen in any of the 48 FHÀ patients (0%). The frequency of this variant was less than 1% in our population study (N ¼ 411; data not shown), suggesting that C315S is a relatively common mutation in ESCC, especially in ESCC cases who are FH þ . Further follow-up of the families studied here in addition to evaluation of C315S and N1600del in additional families will be needed to determine the importance of these mutations in familial ESCC. Of note, all family members, including both carriers and noncarriers, are targeted for our ongoing follow-up program, which will continue to identify new cases and minimize misclassification by disease status in future analyses.
While segregation of disease by mutation was evident in two of our families with germline mutations, for the third family (L002), BRCA2 mutations did not appear to segregate by disease, as one ESCC case was a noncarrier while no disease was apparent in six carriers. In this family, there is a history of EC in both sides of the family (father's side case is the father, 02; mother's side case is the maternal grandmother), which may have some implications for the unusually young age of A2951T (22) 1 (1%) 0 BRCA2 germline mutations in esophageal cancer N Hu et al diagnosis for the proband in this family (i.e., age 39 years). It will be important to continue to follow this family for the development of ESCC, particularly the six carriers who currently have no clinical disease. The role of BRCA2 in FHÀ cases remains to be determined. While we have not yet seen a germline mutation in an FHÀ case, we have found somatic mutations in these cases, although they are relatively infrequent (2/22 or 10%), and approximately the same frequency as somatic BRCA2 mutations in FH þ families (1/34 or 3%).
Most of the BRCA2 germline mutations we detected in ESCC were not truncating mutations and the functional significance of these mutations is unclear. However, at least three mutations (N1600del, A2054P, and V2109I) in exon 11 are located at a conserved sequence region (BRC repeats), and these changes may influence the interaction with RAD51, a critical protein for DNA recombination and double-strand DNA break repair. Of special interest in this regard are the first four of eight BRC repeats found in the 5 0 region of exon 11, which are the most conserved in mammals and bind RAD51 strongly. BRCA2 is involved in DNA singleand double-strand repair, which suggests that genetic changes may result in chromosomal instability and increased genetic susceptibility to cancer. Although yet unproven, there are several alterations observed in this study, with some evidence suggestive of potential functional consequences, including the polymorphisms 203G4A, N372H, K2729N, and I3412V. K2729N, seen in 3% of cases and 3% of controls, is located in the conserved BRCA2 COOH-terminal domain bound to DSS1 (deleted in split-hand/split-foot 1 region), which can associate with BRCA2 in the region of amino acids 2472-2957 (Marston et al., 1999; Yang et al., 2002) . This variant has been reported several times in the BIC database, and a recent study reported that its frequency was less than 1% in 391 Chinese women in Tianjin (Zhi et al., 2002) . I3412V is another interesting variant identified in 13% of ESCC patients in our study, including one patient who also had the germline mutation A2054P. This variant results in the conservative substitution of valine for isoleucine at amino-acid position 3412 in BRCA2. The terminal region of the BRCA2 protein, where this variant is found, can be entirely truncated. The polymorphism 203G4A was seen in 57% of the cases here and, although found in a noncoding region of BRCA2, a recent study showed that only chromosomes carrying G at the 203 position of the 5 0 UTR contributed normal mRNA, and that chromosomes carrying A (adenine) altered the reading frame and did not contribute to the production of normal BRCA2 protein (Pyne et al., 2000) . Polymorphism N372H was identified in 91% of patients tested. Several studies have demonstrated that BRCA2 specifically interacts with histone acetyltransferase P/CAF, which possesses histone acetyltransferase activity. This interaction requires residues 290-453 in the N-terminus of BRCA2 where N372H is located (Fuks et al., 1998) . It is not clear, however, whether the N372H substitution affects this binding. In the future, additional larger epidemiologic studies as well as functional laboratory studies will be required to determine the real role of these alterations in familial as well as sporadic ESCC. In summary, we found a higher frequency of BRCA2 germline mutations in familial ESCC patients than in sporadic patients, suggesting that germline mutations of this gene may be related to genetic susceptibility to familial ESCC in this high-risk area in China.
Materials and methods

Selection of patients and family members
This study was approved by the Institutional Review Boards of the Shanxi Cancer Hospital, the Yangcheng Cancer Hospital, and the US National Cancer Institute. After obtaining informed consent, patients were interviewed to obtain information on demographic and cancer lifestyle risk factors, including tobacco use (yes/no), frequency of alcohol use, pickled vegetable and scalding hot food consumption (never, monthly, weekly, daily), and a detailed family history of cancer (including all cancers in the first-, second-, and third-degree relatives). The definition of the family history of UGI cancer was that there were at least two UGI cancers (defined as esophageal squamous cell carcinoma, gastric cardia cancer (CC), or gastric non-CC; unlike the West, esophageal adenocarcinomas are virtually nonexistent in this area of China and are not included) in the first-, second-or thirddegree relatives in a family. We selected a total of 70 patients for study, including 44 who had a history of UGI cancer (FH þ group; includes 20 from the family study and 24 from the tumor/nontumor study), and 26 with no history of UGI cancer (FHÀ group; all are from the tumor/nontumor study), who had a histologic diagnosis of ESCC confirmed by pathologists at the Shanxi Cancer Hospital, Yangcheng Cancer Hospital, and the NCI. None of the patients had prior therapy and Shanxi was the ancestral home for all. In the FH þ group, 20 of the 46 ESCC cases had family members aged X18 years, who had participated in a family study and had provided similar interview data and a blood sample for DNA testing. For three of these 20 families, data and samples were considered complete, and 28 members of these three families were evaluated as part of the current study.
Selection of healthy individuals from low-and high-risk areas
Two groups of healthy individuals were selected as controls as follows: a low-risk group included 101 individuals (males ¼ 56, females ¼ 45) from Beijing, where crude EC mortality rates are 18.2/100 000 in males and 8.2/100 000 in females (National Cancer Control Office, 1980) ; and a high-risk group was comprised of 131 healthy individuals (males ¼ 80, females ¼ 51) from Yangcheng county, which has one of the highest rates of EC in China (crude EC mortality rates of 167.9/100 000 in males and 94.9/100 000 in females (National Cancer Control Office, 1980) ). The age range for both groups was 35-55 years.
Biologic specimen collection and processing
A volume of 10 ml of venous blood was taken from each patient prior to surgery; a similar amount was obtained from participating family members. The blood from healthy individuals was collected from blood banks in Beijing and Yangcheng. For all participants, genomic DNA was extracted and purified using standard methods. (Salt Lake City, UT, USA, NCI149). The specific mutations identified in patients were then examined in family members and healthy controls by PCR-SSCP and DNA sequencing, as described previously . Primer sequences for alterations in BRCA2 are shown in Table 1 .
